Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Income towards Parent Company (2022 - 2025)

Historic Income towards Parent Company for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$44.2 million.

  • Entrada Therapeutics' Income towards Parent Company fell 21575.19% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 28829.49%. This contributed to the annual value of $65.6 million for FY2024, which is 108780.3% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Income towards Parent Company is -$44.2 million, which was down 21575.19% from -$43.1 million recorded in Q2 2025.
  • Entrada Therapeutics' Income towards Parent Company's 5-year high stood at $55.0 million during Q2 2024, with a 5-year trough of -$44.2 million in Q3 2025.
  • For the 4-year period, Entrada Therapeutics' Income towards Parent Company averaged around -$9.4 million, with its median value being -$17.3 million (2025).
  • As far as peak fluctuations go, Entrada Therapeutics' Income towards Parent Company surged by 44948.68% in 2024, and later plummeted by 21575.19% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Income towards Parent Company (Quarter) stood at -$24.6 million in 2022, then soared by 61.43% to -$9.5 million in 2023, then surged by 111.63% to $1.1 million in 2024, then plummeted by 4098.19% to -$44.2 million in 2025.
  • Its Income towards Parent Company was -$44.2 million in Q3 2025, compared to -$43.1 million in Q2 2025 and -$17.3 million in Q1 2025.